RESEARCH ARTICLE

Factors associated with death and loss to follow-up in children on antiretroviral care in Mingalardon Specialist Hospital, Myanmar, 2006–2016

Kay Khaing Kaung Nyunt1*, Wai Wai Han2*, Srinath Satyanarayana3, Petros Isaakidis4,6, San Hone1†, Aye Aye Khaing6‡, Hoa Nguyen Binh3,7‡, Htun Nyunt Oo1‡

1 National AIDS Programme, Department of Public Health, Ministry of Health and Sports, Nay Pyi Taw, Myanmar, 2 Department of Medical Research, Ministry of Health and Sports, Yangon, Myanmar, 3 Center for Operational Research, International Union Against Tuberculosis and Lung Disease, Paris, France, 4 Médecins Sans Frontières (MSF)/Doctors Without Borders, Mumbai, India, 5 Médecins Sans Frontières (MSF)/Doctors Without Borders, Operational Research Unit, Luxembourg, 6 Mingalardon Specialist Hospital, Department of Medical Care, Ministry of Health and Sports, Yangon, Myanmar, 7 National Tuberculosis Program Vietnam, Hanoi, Vietnam

*These authors contributed equally to this work.
†These authors also contributed equally to this work.
*Kaykhaingo0132@gmail.com

Abstract

Background

Myanmar National AIDS programme’s priority is to improve the survival of all people living with HIV by providing anti-retroviral therapy (ART) care. More than 7200 children (aged <15 years) have been enrolled into ART care from 2005 to 2016. A previous study showed that ~11% children on ART care had either died or were lost to follow-up by 60 months. Factors associated with death and lost-to-follow-up (adverse outcomes) have not been previously studied.

Objectives

To describe the association between demographic and clinical characteristics at enrollment into ART care with adverse outcomes.

Methods

Cohort study using records of children enrolled for ART care at Mingalardon Specialist Hospital (main Paediatric ART center in Myanmar) from 2006–2016. We used multivariable Cox proportional hazards regression models for analysis.

Results

1,159 children were enrolled for ART care and they contributed a total of 1.45 million person-days of follow-up period. 112 (10%) had an adverse outcome during the follow-up time period (55 deaths, 57 lost to follow-up). Enrollment into the ART care through in-patient care department of the hospital, CD4 Cell count <50/mm3, enrollment during changing ART
guidelines (different ART eligibility criteria and preferred ART regimen) were independently associated with higher hazards of adverse outcome. Receiving protease inhibitor-based ART regimen at enrollment was independently associated with lower hazards of adverse outcome. Age, sex, residing in urban or rural areas, WHO clinical stage, having TB at the time of enrollment, receiving cotrimoxazole prophylaxis were not statistically associated with adverse outcomes.

Conclusion

Our analysis reconfirms good survival of children on ART care (including those with TB). The characteristics associated with adverse outcomes (other than CD4 cell count < 50) are surrogates of some unmeasured underlying health system/patient related factors that needs further exploration to improve the survival of children on ART care.

Background

Globally, 36.7 million people are living with HIV (PLHIV) and of these 5.1 million are in the Asia and Pacific Region of the World Health Organisation. There were ~19,000 [16,000–22,000] new HIV infections in children in this region in 2015[1]. By 2016, approximately 127,402 people were enrolled in HIV care in Myanmar and this includes 7,298 children below the age of 15 years [2]. Antiretroviral treatment (ART) services have gradually expanded throughout the country. Currently, 269 health facilities are providing ART care nationwide (219 public sector and 50 NGO/INGO/private sector sites) with the public sector providing ART to 62% of the total PLHIV in the country[3]. The first pediatric ART center was initiated in the public sector in 2005 at Mingalardon Specialist Hospital, Yangon.

Evidence suggests that early HIV diagnosis and ART can reduce mortality by 76% and HIV progression by 75% in HIV infected children [4]. However, ART outcomes among children in Myanmar have not been adequately studied and reported. A PubMed search revealed several pediatric HIV studies from the South East Asia region but none from Myanmar. To our knowledge, there has been only one locally published report describing the mortality/survival of pediatric HIV cohort in the country[5]. This study looked at deaths among children enrolled for ART care from 2005 to 2012 in Mingalardon Specialist Hospital, Yangon and Mandalay Children hospital and reported the cumulative survival probabilities at various time periods. The 12 month and 60 month cumulative survival probabilities were 0.92 and 0.89 respectively[5]. However, this study did not report on the factors associated with adverse treatment outcomes (death and loss to follow-up). Identifying the factors associated with adverse outcomes will help in informing the policies and practices for further improving the survival of children on ART care in the country.

Therefore, the objectives of this study are, a) to describe the demographic and clinical characteristics of the children enrolled for ART care at Mingalardon Specialist Hospital, Yangon from 2006–2016, and b) to assess the association between these demographic and clinical characteristics with adverse treatment outcomes (death and loss to follow-up).

Methods

Design

This was a retrospective cohort study using records of children (aged < 15 years) enrolled for ART care at Mingalardon Specialist Hospital during the period 2006 to 2016.
Study setting

General setting. Myanmar is the largest country in mainland South East Asia with a total land area of 676,578 square kilometers. According to the 2014 Population and Housing Census, 51.4 million people are living in Myanmar with a population density is 76 persons per square kilometer. Approximately 70% of the population resides in rural areas[6]. The country is divided administratively, into Nay Pyi Taw Union Territory and 14 States and Regions. Myanmar health system has primary, secondary and tertiary health care facilities. All regions/states have primary and secondary health care services but tertiary health facilities are only in some large regions. In each region/state there are three to four districts. There are four to five township hospitals in each district and one to two station hospitals and six to seven rural health centres in each township.

Myanmar National AIDS Program (NAP). NAP is one of the disease control programs under Disease Control Unit, Department of Public Health, Ministry of Health and Sports. It was formed in 1989 by integration with existing sexually transmitted diseases program. The major components of the programme are prevention, early diagnosis, providing ART care, monitoring and evaluation. Pediatric ART care was initiated in the public sector in 2005, and currently there are 106 paediatric ART centers. Mingalardon Specialist Hospital in Yangon is one of the main ART centers among them. At this hospital, children can get enrolled into the ART care after being referred from the out-patient department, inpatient department of the hospital, or after referral from any other health facility. Prior to enrollment the child undergoes baseline clinical investigations which includes assessment for WHO stage, CD4 Cell count and opportunistic infections (especially TB). The guidelines for initiating the child on ART were in accordance with the WHO guidelines at different time periods and were revised in 2005, 2007, 2011, 2014 (Table 1) [7–10]. Once enrolled, children visit this center at regular intervals for follow-up evaluations. The details of all children enrolled on ART care is being maintained in an electronic database.

Study population

All HIV positive children aged <15 years who were enrolled for ART care at Mingalardon Specialist Hospital for pediatric ART care between 1st January 2006 to 31st December 2016.

Definitions of outcomes

Each child enrolled into our study was assigned one of these four mutually exclusive outcomes as on 31st March, 2017 (date of censoring).

Alive and on ART care:—Patients who are alive and continue to receive ART care from the ART center.

Death:—patients who have been reported as death from family members during the ART treatment.

Lost to follow up (LTFU)—defined when the patient missing for 3 consecutive months the follow up visit.

Transfer-out:—patients who were transferred to other ART clinics for continuation of care or moved from pediatric ART care to adult ART care (at 15 years of age).

Each child’s duration in ART care was calculated from their date of enrolment into ART care to the date of their outcome or date of censoring (which ever date happened to be earlier). In our study, we defined adverse treatment outcome as any child who has died or was lost-to-follow-up. Children who were “alive and on ART care” or children who were “transferred out” were considered as favorable outcomes.
| Guidelines                        | ART eligibility criteria                                                                 | Preferred ART regimen                      |
|-----------------------------------|-------------------------------------------------------------------------------------------|---------------------------------------------|
| National Guidelines               | • WHO Stage 4 or 3                                                                          | AZT or d4T +3TC+NVP or EFV (if age >3 years) |
| [Guideline 2005]                  | • Age ≤18 months, WHO Stage 1 or 2 with TLC <2500 mm³                                     |                                             |
|                                   | • Age >18 months, WHO Stage 1 or 2 with TLC <1500 mm³                                     |                                             |
|                                   | • If CD4 cell counts are available, then                                                   |                                             |
|                                   | □ Age ≤18 months, any WHO Stage (1/2/3/4) with % CD4 <20%                                 |                                             |
|                                   | □ Age >18 months, any WHO Stage (1/2/3/4) with % CD4 <15%                                 |                                             |
| National Guidelines               | • WHO Stage 3 or 4                                                                          | AZT or d4T +3TC+NVP or EFV (if age >3 years) |
| [Guidelines 2007]                 | • CD4 indicating severe HIV associated immune deficiency                                     |                                             |
|                                   | □ Age <11 months with CD4 <25%                                                             |                                             |
|                                   | □ Age 12–35 months with CD4 <20%                                                           |                                             |
|                                   | □ 36–59 months with CD4 <15%                                                               |                                             |
|                                   | □ ≥5 years with CD4 <15% or CD4 Cell count <200 cells/mm³                                   |                                             |
| National Guidelines               | • All HIV infected children less than 2 years                                             | If age < 2 years                            |
| [Guidelines 2011]                 | • For children >2 years, if WHO Stage 3 or 4                                              | • AZT+3TC+NVP for NVP naïve children         |
|                                   | • For children >2 years, and WHO Stage 1 or 2 if                                            | • AZT+3TC+LPV/r for NNRTI exposed children   |
|                                   | □ Age 2 to 5 years and CD4 cell count ≤750 cells/mm³                                       | If age 2 to 3 years                         |
|                                   | □ Age >5 years and CD4 cell count ≤350 cells/mm³                                          | • AZT or ABC or d4T+3TC+NVP                 |
|                                   | □ If age > 3 years                                                                         |                                             |
|                                   | □ • AZT or ABC or d4T+3TC+NVP or EFV                                                       |                                             |
| National Guidelines               | • All HIV infected children age ≤ 5 years                                                  | If age <3 years (any of the two regimens)    |
| [Guideline 2014]                  | • For children > 5 years, if                                                                | • ABC or AZT+3TC+LPV/r                      |
|                                   | □ CD4 cell count ≤ 500 cells/mm³                                                          | • ABC or AZT+3TC+NVP                        |
|                                   | □ WHO Stage 3 or 4                                                                          | If age 3 to 10 years (any of the four regimens) |
|                                   | □ HIV-TB co infection                                                                      | • ABC+3TC+EFV                              |
|                                   | □ • ABC or AZT+3TC+NVP                                                                     | • ABC or AZT+3TC+EFV                        |
|                                   | □ • TDF+3TC+NVP                                                                           | • TDF+3TC+NVP                               |
|                                   | □ • AZT+3TC+EFV                                                                           | • AZT+3TC+EFV                              |
|                                   | □ If age 10 to 19 years (any of the 3 regimens)                                            | • TDF+3TC+EFV                              |
|                                   | □ • AZT+3TC+NVP                                                                           | • TDF+3TC+EFV                              |
|                                   | □ • TDF+3TC+NVP                                                                           | • TDF+3TC+NVP                               |

ART = Anti-retroviral therapy; HIV = Human immunodeficiency virus (HIV); TLC = Total Leucocyte count; WHO = World Health Organisation; ABC = Abacavir; AZT = Zidovudine; d4T –Stavudine; EFV = Efavirenz, LPV/r- lopinavir boosted ritonavir; NVP = Nevirapine; TDF-Tenofovir disoproxil fumarate; 3TC-lumivudine

https://doi.org/10.1371/journal.pone.0195435.t001
Data variables, sources of data and data collection

Data variables included (i) socio-demographic and clinical characteristics at enrollment into ART care and (ii) treatment outcomes of the HIV infected children. We obtained individual patient data from electronic patient database of Mingalardon Specialist Hospital. The demographic and clinical factors that we assessed for its association with adverse outcomes were those that are routinely maintained in this electronic database. These included age, sex, residence in urban or rural areas, point of entry into ART care (from outpatient department/ or from in-patient care), WHO Stage, CD4 Cell count, and ART guidelines at the time of enrollment, presence or absence of TB at the time of enrollment into ART care, type of TB, ART regimen (NNRTI-based regimen or PI-based regimen) and whether the child received cotrimoxazole prophylaxis for opportunistic infection at enrollment.

Analysis and statistics

Relevant variables from electronic database of the hospital were extracted into Excel and imported to Stata/IC version 12.1 (StataCorp LP, TX, USA) for analysis. The demographic and clinical characteristics of the study population have been described using numbers and proportions. We used unadjusted Kaplan-Meier survival methods and curves to assess the differences in the survival of children with various demographic and clinical characteristics. We used Cox proportional hazards models to estimate the hazard ratios and adjusted hazard ratios (HRs & aHRs) of the association between demographic and clinical factors and adverse treatment outcomes. We assessed for violations of the proportionality assumption using schoenfeld and scaled schoenfeld residuals (using stptest command in Stata). The factors that were included in multivariable model to estimate adjusted hazard ratios included variables that were significantly associated at the bi-variate level or were known to be previously associated with adverse outcomes in published literature. Statistical significance was set at 0.05.

Ethics

Ethics approval was obtained from Ethics Review Committee of Department of Medical Research, Ministry of Health and Sports, Myanmar (ERC Approval Number Ethics/DMR/2017/028) and the Ethics Advisory Group of The Union, Paris, France (86/16). The Director of Disease Control Programmes, Ministry of Health and Sports, Myanmar approved to use the patient data for this study.

Results

From 2006 to 2016, 1,159 children were enrolled for ART care. Their demographic characteristics are described in Table 2 along with the time period of enrollment into ART care. Nearly half (53%) were males with three fourths (76%) being children in the age group 1–10 years. Majority of them (83%) were from urban areas and their main entry point into ART care was referral from out-patient departments (78%). Mother to child transmission was the predominant mode of HIV infection for almost all of them (95%).

Table 3 shows their clinical characteristics. Nearly 70% were in WHO stage 3 or stage 4. Nearly half (51%) of them had CD4 cell counts less than 350 cells/mm³ with about one fifth (17%) having CD4 count <50 cells/mm³. More than half of them (58%) had tuberculosis (predominantly pulmonary TB) at the time of enrollment. Cotrimoxazole prophylaxis for opportunistic infections was given to a large proportion of children at enrolled (83%). Most of them (94%) received Non-nucleoside reverse transcriptase inhibitor (NNRTI) based regimen at
enrollment and majority (86%) were alive and still on ART care at this center on the date of censoring.

The children cumulatively contributed a total of 1,453,260 child-days of follow-up time period on pediatric ART care, 54 (4%) were transferred from this center and 112 (10%) children had an unfavorable outcome (death or loss to follow-up). The overall median duration of follow-up was 1110 days (Interquartile range: 539–1974 days). The median duration of follow-up time period in children who were lost to follow-up was 111 days (Interquartile range: 42–413 days) and in those who had died was 48 days (interquartile range: 19–158 days).

Initial bivariate analysis using Kaplan-Meir survival curves (log rank test chi-square p-value <0.05) indicated age group, point of entry into ART care, CD4 cell count category, ART guideline being followed at the time of entry into the cohort, and the ART regimen (NNRTI-based regime or PI-based regime) that the child received at enrollment were statistically associated with adverse outcomes [Figs (1–4)].

Table 4 shows the unadjusted and adjusted hazard ratios of the association between demographic-clinical factors and adverse outcomes. On bivariate analysis, age group, WHO stage, point of entry into ART care, CD4 cell count, ART guideline at the time of enrollment, were statistically associated with adverse outcome. On multi-variable analysis point of entry into ART care, CD4 Cell count, ART guideline at the time of enrollment, the regimen that the child received at enrollment were statistically associated with adverse outcomes.

Children enrolled into the ART program through the in-patient care department or those whose referral to ART care center status was ‘unknown’ had higher hazards of adverse outcome when compared to children who entered into ART care after referral from the outpatient department. Within the CD4 count categories, those having CD4 cell count less than 50 cells/mm$^3$ or those children whose CD4 Cell count wasn’t available had a higher hazard of

Table 2. Socio-demographic characteristics of HIV positive children (<15 years of age) [N = 1159] enrolled for Antiretroviral therapy in Mingalardon Specialist Hospital in Yangon between 2006 and 2016.

| Socio-demographic characteristics | Overall | 2006–2009 | 2010–2013 | 2014–2016 |
|----------------------------------|---------|-----------|-----------|-----------|
|                                  | Number (%) (Column) | Number % (row) | Number % (row) | Number % (row) |
| **Age**                          |         |           |           |           |
| < 1 years                        | 83 7.2  | 2 2.4     | 30 36.1   | 51 61.4   |
| 1–5 years                        | 397 34.2| 59 14.9   | 149 37.5  | 189 47.6  |
| 5–10 years                       | 482 41.6| 78 16.2   | 156 32.4  | 248 51.5  |
| >10–15 years                     | 197 17  | 16 8.1    | 68 34.5   | 113 57.4  |
| **Sex**                          |         |           |           |           |
| Male                             | 610 52.6| 77 12.6   | 217 35.6  | 316 51.8  |
| Female                           | 549 47.4| 78 14.2   | 186 33.9  | 285 48.1  |
| **Permanent Address**            |         |           |           |           |
| Urban                            | 965 83.3| 154 16    | 356 36.9  | 455 47.2  |
| Rural                            | 194 16.7| 1 0.5     | 47 24.2   | 146 75.3  |
| **Entry point of care**          |         |           |           |           |
| Out-patient                      | 906 78.2| 132 14.6  | 358 39.5  | 416 45.9  |
| In-patient                       | 228 19.7| 11 4.8    | 35 15.4   | 182 79.8  |
| Others                           | 18 1.5  | 10 55.6   | 6 33.3    | 2 11.1    |
| Unknown                          | 7 0.6   | 2 28.6    | 4 57.1    | 1 14.3    |
| **Risk factor of patients**      |         | 50.0      | 50.0      | 0 0.0     |
| Blood transfusion                | 2 0.2   | 1 50.0    | 1 50.0    | 0 0.0     |
| Mother to child                  | 1100 94.9| 151 13.7  | 365 33.2  | 584 53.1  |
| Unknown                          | 57 4.9  | 3 5.3     | 37 64.9   | 17 29.8   |

https://doi.org/10.1371/journal.pone.0195435.t002
adverse outcome when compared to those with CD4 cell count >500 cells/mm$^3$. Those who were enrolled at the time of 2005 ART guideline, 2011 or 2014 ART guideline had higher hazards of adverse outcome when compared with children who were enrolled at the time of 2007 ART guidelines. Children who received Protease inhibitor based ART regimen at enrollment had lower hazards of adverse outcome when compared to children who received NNRTI based regime.

**Discussion**

In children enrolled for ART care at Mingalardon specialist hospital from 2006 to 2016, ~10% had an adverse outcome by 31st March, 2017. To our knowledge, this is the first manuscript

---

Table 3. Clinical characteristics of HIV positive children (<15 years of age) [N = 1159] at enrolment into Anti-Retroviral therapy Care (ART) care in Mingalardon Specialist Hospital in Yangon between 2006 and 2016.

| Clinical characteristics | Overall | 2006–2009 | 2010–2013 | 2014–2016 |
|--------------------------|---------|-----------|-----------|-----------|
|                         | Number  | % (column)| Number    | % (row)   |
| WHO Staging             |         |           |           |           |
| - Stage 1               | 231     | 19.9      | 1         | 0.4       |
| - Stage 2               | 109     | 9.4       | 4         | 3.7       |
| - Stage 3               | 623     | 53.8      | 111       | 17.8      |
| - Stage 4               | 196     | 16.9      | 39        | 19.9      |
| CD4 Count baseline      |         |           |           |           |
| - <50 cells/mm$^3$      | 199     | 17.2      | 38        | 19.1      |
| - 50–200 cells/mm$^3$   | 246     | 21.2      | 29        | 11.8      |
| - 201–350 cells/mm$^3$  | 147     | 12.7      | 23        | 15.6      |
| - 351–500 cells/mm$^3$  | 120     | 10.4      | 19        | 15.8      |
| - >500 cells/mm$^3$     | 384     | 33.1      | 34        | 8.9       |
| - Missing               | 63      | 5.4       | 12        | 19.0      |
| TB                      |         |           |           |           |
| - Yes                   | 674     | 58.2      | 121       | 18.0      |
| - No                    | 485     | 41.8      | 34        | 7.0       |
| TB status during ART treatment | | | | |
| - Pulmonary TB (Smear +) | 4       | 0.6       | 1         | 25.0      |
| - Pulmonary TB (smear -) | 116     | 17.2      | 60        | 51.7      |
| - Extra Pulmonary TB    | 51      | 7.6       | 8         | 15.7      |
| - Pulmonary TB          | 465     | 69        | 43        | 9.2       |
| - Missing               | 38      | 5.6       | 9         | 23.7      |
| Prophylaxis for OI      |         |           |           |           |
| - Yes                   | 960     | 82.8      | 143       | 14.9      |
| - No                    | 199     | 17.2      | 12        | 13.4      |
| Outcome of ART patients |         |           |           |           |
| - Alive and on ART      | 993     | 85.7      | 116       | 11.7      |
| - Death                 | 57      | 4.9       | 10        | 17.5      |
| - Lost to follow up     | 55      | 4.7       | 6         | 10.9      |
| - Transfer out          | 54      | 4.7       | 23        | 42.6      |
| Regime of ART patients  |         |           |           |           |
| -NNRTI based regime     | 1092    | 94.2      | 137       | 12.5      |
| - PI based regime       | 67      | 5.8       | 18        | 26.9      |

NNRTI-Non-Nucleoside reverse-transcriptase inhibitor; PI-Protease inhibitor; OI-opportunistic infection; CD4-CD4 + T lymphocyte count.

https://doi.org/10.1371/journal.pone.0195435.t003
from Myanmar to describe the association between demographic-clinical characteristics at enrollment into ART care and adverse outcomes.

The major strengths of our study includes a large cohort of children that represents ~15% of 7298 children ever enrolled into ART care in Myanmar till 2016, with nearly 1.5 million person-days of follow-up time period data. In addition, we did not exclude any children. More than 95% of the children had data on all the study variables. Therefore, our study findings are likely to be robust.

Fig 1. Unadjusted Kaplan-Meier survival curves for treatment outcome of HIV positive children who receiving ART in Mingalarodon Specialist Hospital by entry point of care (2006 to 2016). Log rank test chi² p-value: 0.0000.

https://doi.org/10.1371/journal.pone.0195435.g001

Fig 2. Unadjusted Kaplan-Meier survival curves for treatment outcome of HIV positive children who receiving ART in Mingalarodon Specialist Hospital by CD4 count (2006 to 2016). Log rank test chi² p-value: 0.0001.

https://doi.org/10.1371/journal.pone.0195435.g002
There are three major limitations of this study: First, we used routinely collected programme data for our analysis and therefore we are unable to rule out measurement/misclassification errors. As standard procedures are being followed for obtaining patient information and with relatively well defined supervision and monitoring systems, the measurement errors are likely to be minimal & random. Therefore, our study results are unlikely to be biased due to these errors. Second, our study reflects the survival of children on pediatric ART care and does not provide any information on the survival of these children when they move into adult ART care after attaining 15 years of age. Third, we did not have information on a couple of

---

Fig 3. Unadjusted Kaplan-Meier survival curves for treatment outcome of HIV positive children who receiving ART in Mingalardon Specialist Hospital by guideline (2006 to 2016). Log rank test chi^2 p-value: 0.0042.

https://doi.org/10.1371/journal.pone.0195435.g003

Fig 4. Unadjusted Kaplan-Meier survival curves for treatment outcome of HIV positive children who receiving ART in Mingalardon Specialist Hospital by regime of ART patients (2006 to 2016). Log rank test chi^2 p-value: 0.0531.

https://doi.org/10.1371/journal.pone.0195435.g004
Table 4. Socio-demographic and clinical factors associated with adverse outcome of HIV positive children (age<15 years) [N = 1159] at Mingalaron Specialist Hospital from 2006 to 2016.

| Variable                        | Number (N) | Adverse outcome |
|---------------------------------|------------|-----------------|
|                                | n | % | Unadjusted HR | 95% CI | P-Value | Adjusted HR | 95% CI | P-value |
| Age                             |   |   |               |        |         |             |        |         |
| <1 years                        | 83 | 14 | 16.9 | 2.31 | (1.25–4.27) | 0.007 | 1.8 | (0.94–3.38) | 0.076 |
| 1–5 years                       | 397 | 36 | 9.1  | 1.14 | (0.72–1.80) | 0.563 | 1.4 | (0.87–2.26) | 0.158 |
| 5–10 years                      | 482 | 40 | 8.3  | 1.47 | (0.87–2.49) | 0.145 | 1.4 | (0.78–2.31) | 0.272 |
| >10–15 years                    | 197 | 22 | 11.2 | 1.47 | Reference |
| Sex                             |   |   |     |      |         |         |     |         |
| Male                            | 610 | 58 | 9.5  | 0.93 | (0.64–1.35) | 0.710 | 0.9 | (0.63–1.36) | 0.73 |
| Female                          | 549 | 54 | 9.8  | 1.46 | (0.92–2.32) | 0.104 | 1.1 | (0.67–1.79) | 0.693 |
| Permanent Address               |   |   |     |      |         |         |     |         |
| Urban                           | 965 | 88 | 9.1  | 1.24 | (1.14–2.32) | 0.104 | 1.1 | (0.67–1.79) | 0.693 |
| Rural                           | 194 | 24 | 12.4 | 1.46 | (0.92–2.32) | 0.104 | 1.1 | (0.67–1.79) | 0.693 |
| Entry point of care             |   |   |     |      |         |         |     |         |
| Out-patient                     | 906 | 62 | 6.8  | 1.24 | (0.92–2.32) | 0.104 | 1.1 | (0.67–1.79) | 0.693 |
| In-patient                      | 228 | 46 | 20.2 | 3.62 | (2.45–5.34) | <0.001 | 2.6 | (1.68–4.06) | <0.001 |
| Others                          | 18  | 1  | 5.6  | 0.76 | (0.10–5.49) | 0.788 | 0.7 | (0.09–5.21) | 0.729 |
| Unknown                         | 7   | 3  | 42.9 | 9.36 | (2.93–29.87)| <0.001 | 7.1 | (1.96–25.88)| 0.003 |
| WHO Staging                     |   |   |     |      |         |         |     |         |
| Stage 1                         | 231 | 12 | 5.2  | 1.24 | (0.92–2.32) | 0.104 | 1.1 | (0.67–1.79) | 0.693 |
| Stage 2                         | 109 | 11 | 10.1 | 1.79 | (0.79–4.07) | 0.161 | 1.4 | (0.59–3.26) | 0.446 |
| Stage 3                         | 623 | 59 | 9.5  | 1.53 | (0.82–2.87) | 0.177 | 1.0 | (0.47–2.18) | 0.966 |
| Stage 4                         | 196 | 30 | 15.3 | 2.4  | (1.22–4.73) | 0.011 | 1.3 | (0.53–2.91) | 0.603 |
| CD4 Count baseline              |   |   |     |      |         |         |     |         |
| <50 cells/mm3                   | 199 | 34 | 17.1 | 2.52 | (1.50–4.24) | <0.001 | 2.3 | (1.27–4.06) | 0.005 |
| 50–200 cells/mm3                | 246 | 24 | 9.8  | 1.45 | (0.83–2.54) | 0.191 | 1.3 | (0.74–2.45) | 0.326 |
| 201–350 cells/mm3               | 147 | 11 | 7.5  | 1.09 | (0.54–2.23) | 0.794 | 1.2 | (0.58–2.48) | 0.616 |
| 351–500 cells/mm3               | 120 | 5  | 4.2  | 0.6  | (0.23–1.57) | 0.299 | 0.7 | (0.26–1.83) | 0.467 |
| >500 cells/mm3                  | 384 | 26 | 6.8  | 2.4  | (1.22–4.73) | 0.011 | 1.3 | (0.53–2.91) | 0.603 |
| Missing                         | 63  | 12 | 19.0 | 3.06 | (1.54–6.10) | 0.001 | 2.3 | (1.09–4.84) | 0.028 |
| ART Guideline                   |   |   |     |      |         |         |     |         |
| Guideline 2005                  | 39  | 8  | 20.5 | 3.99 | (1.54–10.31)| 0.004 | 2.8 | (0.99–8.02) | 0.05  |
| Guideline 2007                  | 221 | 11 | 5.0  | Reference |
| Guideline 2011                  | 477 | 59 | 12.4 | 2.97 | (1.54–5.72) | 0.001 | 2.1 | (1.06–4.23) | 0.033 |
| Guideline 2014                  | 422 | 34 | 8.1  | 2.54 | (1.25–5.14) | 0.009 | 1.8 | (0.79–3.87) | 0.166 |
| TB at enrollment                |   |   |     |      |         |         |     |         |
| Yes                             | 674 | 77 | 11.4 | 1.46 | (0.97–2.18) | 0.064 | 1.2 | (0.66–1.93) | 0.591 |
| No                              | 485 | 35 | 7.2  | 1.46 | (0.97–2.18) | 0.064 | 1.2 | (0.66–1.93) | 0.591 |
| Prophylaxis for OI              |   |   |     |      |         |         |     |         |
| Yes                             | 960 | 94 | 9.8  | 0.99 | (0.59–1.64) | 0.978 | 1.1 | (0.61–1.82) | 0.843 |
| No                              | 199 | 18 | 9.0  | 1.46 | (0.97–2.18) | 0.064 | 1.2 | (0.66–1.93) | 0.591 |
| Regime of ART patients          |   |   |     |      |         |         |     |         |
| NNRTI based regime              | 1092| 109| 10.0 | Reference |
| PI based regime                 | 67  | 3  | 4.5  | 0.27 | (0.06–1.11) | 0.093 | 0.2 | (0.05–0.95) | 0.043 |

HR = Hazard ratios; CD4 = CD4 + T lymphocyte count; ART = Anti-retroviral therapy; OI = Opportunistic infection; NNRTI = Non-nucleoside reverse-transcriptase inhibitors; PI = Protease Inhibitor.

https://doi.org/10.1371/journal.pone.0195435.t004
important clinical factors that are associated with adverse outcomes in other studies such as nutritional status and baseline HIV viral load at entry and therefore we are unable to report in our cohort. By taking this opportunity, we can advocate the program for routine viral load monitoring in Myanmar as soon as possible.

Apart from low CD4 count, the other factors that we found associated with adverse outcomes are to be considered as independent predictors of long term adverse outcomes at enrollment into ART care. We strongly believe that these factors are surrogates of some unmeasured patient or health system characteristic that led them to have an association with the adverse outcome. For instance, relatively higher hazards of adverse outcomes in children referred from in-patient department in comparison to those referred from outpatient department of the hospital, most likely indicates that these children had some serious life threatening illness. Similarly, relatively higher hazards of death among children who were enrolled during 2005, 2011 and 2014 guidelines when compared to children enrolled during 2007 guidelines likely reflects health system, patient factors prevalent at those time periods and should not be interpreted as the effectiveness of these guidelines.

In our setting we observed lower hazards of adverse outcome in children (n = 67) who were initiated on PI based ART regimen at enrollment when compared to NNRTI based regimen. The exact reasons why some of these children were initiated on PI based regimen is not documented in our records and therefore we are unable to provide this information. This could be due to the unmeasured differences in the children’s ART therapy intake history prior to enrollment into HIV care at our hospital which led to prescription of protease inhibitor-based regime. This should not be construed as evidence for protease inhibitor-based regimen being more efficacious than NNRTI based regimen. Identifying the real underlying causes that lead to better outcome in children initiated on PI based regimen when compared to NNRTI based regimen is a potential area for future research.

Apart from this, our study findings are consistent with the high cumulative survival probabilities reported in pediatric ART cohorts from our hospital (previously) and in other countries such as Cambodia, Malawi, Lesotho, Swaziland[11–13]. In addition, non-finding of statistically significant differences in the hazards of outcome in children of all age groups, gender, residing in urban or rural areas, with or without TB at enrollment likely indicates that the pediatric ART services are being implemented efficiently with good co-ordination between HIV and TB control programmes in providing services to co-infected patients.

There were a couple of findings that suggest possible areas for further improvement. First, a large number of children entered into the pediatric ART cohort after 1 year of age. Since most of them had acquired infection through their mothers, there should be more focus on preventing the mother to child transmission of HIV infection, early diagnosis of HIV infection in children at risk of mother to child transmission. Therefore strengthening prevention of mother to child transmission programme for early diagnosis of HIV infection in children may be required. Second, nearly half of the children had tuberculosis at diagnosis. This proportion is relatively high when compared to TB at enrolment seen in other countries indicating possibly delays in HIV diagnosis or delays in enrolling children on ART care without tuberculosis. The specific reasons for these delays need further evaluation.

Finally, it is commendable to note that pediatric ART center at this hospital has maintained electronic database of all children ever enrolled into pediatric ART care since its inception in 2005. This allowed us to use this database to conduct our study and assess long term survival in children. The maintenance of electronic database can act as a model for other similar centers in the world.

In conclusion, only 10% of the children ever enrolled into pediatric ART care had an adverse outcome (death or loss to follow-up) in the pediatric cohort with nearly 1.5 million
person days of follow-up. This indicates good survival and/or good pediatric care programme implementation and this should continue. Of all the major demographic and clinical factors at enrollment, those associated with adverse outcomes included entry into ART care from in-patient department, CD4 Cell count <50, enrollment during 2005, 2011 and 2014 ART guideline periods. Identifying the underlying causes for these factors to be associated with adverse outcomes is a potential area for future research and this research is needed to identify the interventions for further improving the survival of children in ART care in Myanmar.

Acknowledgments

This research was conducted through the Structured Operational Research and Training Initiative (SORT IT), a global partnership led by the Special Programme for Research and Training in Tropical Diseases at the World Health Organization (WHO/TDR). The model is based on a course developed jointly by the International Union Against Tuberculosis and Lung Disease (The Union) and Médecins sans Frontières (MSF/Doctors Without Borders). The specific SORT IT programme which resulted in this publication was jointly organized and implemented by: The Centre for Operational Research, The Union, Paris, France; The Department of Medical Research, Ministry of Health and Sports, Myanmar; The Department of Public Health, Ministry of Health and Sports, Myanmar; The Union Country Office, Mandalay, Myanmar; The Union South-East Asia Office, New Delhi, India; the Operational Research Unit (LUXOR), MSF Brussels Operational Center, Luxembourg; Burren Institute, Australia.

Author Contributions

Conceptualization: Kay Khaing Kaung Nyunt, Wai Wai Han, Srinath Satyanarayana, Petros Isaakidis, San Hone, Hoa Nguyen Binh, Htun Nyunt Oo.

Data curation: Kay Khaing Kaung Nyunt.

Formal analysis: Kay Khaing Kaung Nyunt, Wai Wai Han, Srinath Satyanarayana, Petros Isaakidis, Hoa Nguyen Binh.

Investigation: Kay Khaing Kaung Nyunt.

Methodology: Kay Khaing Kaung Nyunt, Wai Wai Han, Petros Isaakidis, San Hone, Hoa Nguyen Binh, Htun Nyunt Oo.

Software: Kay Khaing Kaung Nyunt, Wai Wai Han, Srinath Satyanarayana, Hoa Nguyen Binh.

Supervision: Kay Khaing Kaung Nyunt, Htun Nyunt Oo.

Validation: Kay Khaing Kaung Nyunt, Wai Wai Han, Srinath Satyanarayana, Petros Isaakidis, San Hone, Hoa Nguyen Binh, Htun Nyunt Oo.

Visualization: Kay Khaing Kaung Nyunt, Wai Wai Han, Srinath Satyanarayana, Petros Isaakidis, San Hone, Hoa Nguyen Binh, Htun Nyunt Oo.

Writing – original draft: Kay Khaing Kaung Nyunt, Wai Wai Han, Srinath Satyanarayana, Petros Isaakidis, San Hone, Aye Aye Khaing, Hoa Nguyen Binh, Htun Nyunt Oo.

Writing – review & editing: Kay Khaing Kaung Nyunt, Wai Wai Han, Srinath Satyanarayana, Petros Isaakidis, San Hone, Aye Aye Khaing, Hoa Nguyen Binh, Htun Nyunt Oo.
References

1. UNAIDS. HIV/AIDS Fact sheet 2016 [Internet]. UNAIDS. Geneva; 2016. Available: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf

2. Survey PB, Survey H, Survey H, Report S, Hiv N, Survey S, et al. GARPR Online Reporting Tool—1.5 [Internet]. 2014. Available: http://www.unaids.org/sites/default/files/media_asset/2017-Global-AIDSMonitoring_en.pdf

3. National AIDS Program. Myanmar National Strategic Plan on HIV/AIDS 2016–2020. Ministry of Health and Sports Myanmar; 2016 [Internet]. 2016. Available: http://www.moh.gov.mm/Content/publication/list?pagenumber=1&pagesize=12

4. Ph D, Steyn J, Sc M, Madhi SA, Paed FC, Ph D, et al. NIH Public Access. Early Antiretrovir Ther Mortal among HIV-Infected Infants. 2010; 359: 2233–2244. https://doi.org/10.1056/NEJMoa0800971. Early

5. Mon KL, Mya K, Zaw KK. Survival of HIV Infected Children on Antiretroviral Therapy. Myanmar Health Science Research Journal, Vol 28, No 1, 2016 Survival. 2016;28: 1–4.

6. Myanmar Government. The 2014 Myanmar Population and Housing Census Kachin State The 2014 Myanmar Population and Housing Census. Nay Pyi Taw; 2015.

7. National AIDS Program. Guideline for the Clinical Management of HIV Infection in children in Myanmar. Department of Health, Ministry of Health Myanmar; 2014.

8. National AIDS Program. Guideline for the Clinical Management of HIV Infection in children in Myanmar. Department of Health, Ministry of Health Myanmar; 2011.

9. National AIDS Program. Guideline for the Clinical Management of HIV Infection in children in Myanmar. Department of Health, Ministry of Health Myanmar; 2007.

10. National AIDS Program. Guideline for the Clinical Management of HIV Infection in children in Myanmar. Department of Health, Ministry of Health Myanmar; 2005.

11. Raguenaud M-E, Isaakidis P, Zachariah R, Te V, Soeung S, Akao K, et al. Excellent outcomes among HIV+ children on ART, but unacceptably high pre-ART mortality and losses to follow-up: a cohort study from Cambodia. BMC Pediatr. 2009; 9: 54. https://doi.org/10.1186/1471-2431-9-54 PMID: 19691853

12. Isaakidis P, Raguenaud M-E, Te V, Tray CS, Akao K, Kumar V, et al. High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia. J Int AIDS Soc. Switzerland; 2010; 13: 11. https://doi.org/10.1186/1758-2652-13-11 PMID: 20302672

13. Kabue MM, Buck WC, Wanless SR, Cox CM, McCollum ED, Caviness AC, et al. Mortality and Clinical Outcomes in HIV-Infected Children on Antiretroviral Therapy in Malawi, Lesotho, and Swaziland. Pediatrics. 2012; 130: e591–e599. https://doi.org/10.1542/peds.2011-1187 PMID: 22891234